Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
701-720 of 1,694 trials

Ulcerative Colitis and Crohn's Disease: Vedolizumab IV in Kids

We are studying the long-term safety of vedolizumab IV in children and teenagers with ulcerative colitis or Crohn's disease. This research aims to understand its effects on health and quality of life.

Active Ulcerative Colitis or Crohn's Disease>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterology

Ivosidenib for Acute Myeloid Leukemia After Stem Cell Transplant

We are studying whether Ivosidenib can help patients with acute myeloid leukemia or high-risk myelodysplastic neoplasia stay healthy after a stem cell transplant. This trial focuses on those with an IDH1 mutation to see if it improves their chances of remaining disease-free.

Acute Myeloid Leukemia (AML)Myelodysplastic Neoplasia (MDS)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Small Cell Lung Cancer: AL8326 Treatment Study

We are evaluating the safety and effectiveness of the drug AL8326 for patients with small cell lung cancer who have already received prior treatment. This study aims to find the best dose and understand how well the drug works.

Small Cell Lung Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPulmonology

Idiopathic Pulmonary Fibrosis: Buloxibutid Study

We are testing a new medication, buloxibutid, to see if it helps improve lung function and quality of life for people with idiopathic pulmonary fibrosis. The study compares its effects to a placebo over time.

Idiopathic Pulmonary Fibrosis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Lung Cancer: Repotrectinib for Elderly Patients

We are studying the effectiveness of Repotrectinib in frail or elderly patients with advanced lung cancer. The trial aims to see if this treatment can improve tumor response and overall health.

Stage III/IV Non-Small-Cell Lung Cancer with ROS1 Rearrangement>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyPulmonology

Crohn's Disease: New Treatment Target Study

We are investigating if aiming for complete healing of all bowel layers improves outcomes for patients with active Crohn's disease. This study compares different treatment strategies to see which is more effective.

Crohn's Disease1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

TMJ Arthritis: Cortisone Injection vs. Arthrocentesis

We are comparing the effectiveness of a cortisone injection and a procedure called arthrocentesis for relieving pain in people with TMJ arthritis. We also want to see how these treatments affect mouth opening and if other factors play a role in recovery.

Temporomandibular Joint Arthritis3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesOrthopedics and Traumatology

Sotagliflozin for Post-Bariatric Hypoglycaemia

We are studying whether sotagliflozin can help people who have low blood sugar after weight loss surgery. Participants will receive either the medication or a placebo to compare effects on blood sugar levels.

Postbariatric Hypoglycemia≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementEndocrinologyInternal Medicine

Atopic Dermatitis in Children: Abrocitinib Study

We are investigating the effectiveness and safety of Abrocitinib for children aged 6 to under 12 with moderate-to-severe atopic dermatitis. The study will compare it to a placebo while using other topical treatments.

Moderate-to-Severe Atopic Dermatitis3-6 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyDermatology

Fecal Microbiome Transplantation for Decompensated Cirrhosis

We are studying whether fecal microbiome transplantation can help slow the progression of decompensated cirrhosis in patients. The trial will assess its effects on survival, complications, and overall health.

Decompensated Cirrhosis1-2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesGastroenterologyHepatology

Targeted Anti-Cancer Drugs: DRUP Trial

We are studying how well existing targeted drugs work for patients with advanced cancers that have specific genetic markers. This trial aims to improve access to effective treatments and gather important data on their use.

Non-Hodgkin LymphomaAdvanced Solid TumorT-cell Prolymphocytic Leukemia3-6 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Sickle Cell Disease: Etavopivat Treatment Study

We are evaluating how well etavopivat works for adolescents and adults with sickle cell disease. The study aims to see if it improves symptoms and quality of life compared to a placebo.

Sickle Cell Disease>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Hand Osteoarthritis: Metformin Treatment

We are investigating whether metformin can reduce finger joint pain in people with hand osteoarthritis. This study compares its effects to a placebo over 16 weeks.

Hand Osteoarthritis3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineRheumatology

Kidney Function: Vonafexor Study

We are studying the effects of vonafexor on kidney function in people with impaired renal function and suspected MASH. The trial will help us understand how different doses impact kidney health and safety.

Impaired Renal Function and Suspected MASH6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyNephrology

BRAF-V600E Mutant Metastatic Colorectal Cancer: BRAVE Trial

We are studying a combination of encorafenib, cetuximab, and bevacizumab for patients with BRAF-V600E mutated metastatic colorectal cancer who have not responded to previous treatments. The trial aims to evaluate the safety and effectiveness of this treatment approach.

Metastatic Colorectal Cancer6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

Spinal Cord Injury: TZ-161 Treatment Study

We are testing a new treatment for adults with early acute spinal cord injury to see if it is safe and effective compared to standard care. The study will also evaluate its effects on pain and recovery time.

Early Acute Spinal Cord Injury1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesNeurology

Cytisine vs. Nicotine Replacement Therapy for Smokers with Chronic Kidney Disease

We are studying whether cytisine can help nicotine-dependent patients with chronic kidney disease quit smoking more effectively than traditional nicotine replacement therapy. This trial will also look at any side effects from both treatments.

Nicotine DependenceChronic Kidney DiseaseMonitoring phase (IV)No PlaceboStandard MedicinesNephrologyPsychiatry

Asthma Treatment: Atuliflapon Study

We are investigating whether Atuliflapon can improve symptoms in adults with moderate to severe uncontrolled asthma. This study compares its effects to a placebo to ensure safety and efficacy.

Moderate-to-Severe Uncontrolled Asthma3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyPulmonology

Ulcerative Colitis in Kids: Ozanimod Study

We are testing the oral medication ozanimod in children with moderately to severely active ulcerative colitis who haven't responded to other treatments. The goal is to see if it helps improve their symptoms and overall health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Indolent Non-Hodgkin's Lymphoma: EO2463 Cancer Vaccine

We are investigating a new cancer vaccine, EO2463, for patients with indolent Non-Hodgkin's Lymphoma. The trial aims to assess its safety and effectiveness alone and with other treatments.

Indolent Non-Hodgkin's Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology